ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Back to Protocols
Beginner
16 weeks

Longevity Protocol

Comprehensive anti-ageing targeting telomeres, immune function, and cellular repair

Peptide Stack

Preparation

Reconstitute all peptides with bacteriostatic water. Epitalon is used in a 10-day cycle at the start. Thymosin Alpha-1 and GHK-Cu continue throughout. Store at 2-8°C.

Administration

Week 1-2: Epitalon daily (10 days), plus Thymosin Alpha-1 twice weekly and GHK-Cu daily. Week 3-16: Continue Thymosin Alpha-1 twice weekly and GHK-Cu daily. All injections subcutaneous.

Monitoring

Track energy levels, sleep quality, skin appearance, immune function (frequency of illness), and overall vitality. Consider baseline and follow-up blood work for inflammatory markers and immune function.

Expected Timeline

Week 1-4: Improved sleep and energy. Week 5-8: Enhanced immune function and skin quality. Week 9-16: Continued cellular repair and anti-ageing benefits. Long-term benefits accumulate with repeated cycles.

Research Basis

Epitalon regulates telomerase for telomere maintenance. Thymosin Alpha-1 restores immune function and T-cell activity. GHK-Cu promotes tissue repair and collagen synthesis. Together, they target multiple hallmarks of ageing.

Safety Considerations

  • Do not use if you have active cancer
  • Avoid during pregnancy or breastfeeding
  • Monitor for immune system changes
  • Consult with a healthcare professional before starting
  • This protocol is for research and educational purposes only

Protocol Overview

A comprehensive anti-aging protocol targeting multiple hallmarks of aging. Epithalon for telomere maintenance, Thymosin Alpha-1 for immune restoration, and GHK-Cu for tissue-level repair and collagen synthesis.

Duration: 16 weeks Peptides: 3 Experience Level: Beginner

Peptide Stack

EPITALON

  • Dose: 5-10 mg
  • Frequency: daily for 10 days
  • Timing: evening (cycle: 10 days on, rest of protocol off)

View EPITALON Profile

THYMOSIN-ALPHA-1

  • Dose: 1.6 mg
  • Frequency: twice weekly
  • Timing: any time of day

View THYMOSIN-ALPHA-1 Profile

GHK-CU

  • Dose: 1-2 mg
  • Frequency: daily
  • Timing: evening

View GHK-CU Profile

Preparation

Reconstitute all peptides with bacteriostatic water. Epitalon is used in a 10-day cycle at the start. Thymosin Alpha-1 and GHK-Cu continue throughout. Store at 2-8°C.

Administration

Week 1-2: Epitalon daily (10 days), plus Thymosin Alpha-1 twice weekly and GHK-Cu daily. Week 3-16: Continue Thymosin Alpha-1 twice weekly and GHK-Cu daily. All injections subcutaneous.

Monitoring

Track energy levels, sleep quality, skin appearance, immune function (frequency of illness), and overall vitality. Consider baseline and follow-up blood work for inflammatory markers and immune function.

Expected Timeline

Week 1-4: Improved sleep and energy. Week 5-8: Enhanced immune function and skin quality. Week 9-16: Continued cellular repair and anti-ageing benefits. Long-term benefits accumulate with repeated cycles.

Research Basis

Epitalon regulates telomerase for telomere maintenance. Thymosin Alpha-1 restores immune function and T-cell activity. GHK-Cu promotes tissue repair and collagen synthesis. Together, they target multiple hallmarks of ageing.

Safety Considerations

  • Do not use if you have active cancer
  • Avoid during pregnancy or breastfeeding
  • Monitor for immune system changes
  • Consult with a healthcare professional before starting
  • This protocol is for research and educational purposes only

Disclaimer: This protocol is for educational and research purposes only. It is not medical advice. Consult with a qualified healthcare professional before starting any peptide protocol. These compounds are not approved by the MHRA for human therapeutic use.

Important Disclaimer: This protocol is for educational and research purposes only. It is not medical advice. Consult with a qualified healthcare professional before starting any peptide protocol. These compounds are not approved by the MHRA for human therapeutic use.